IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4.

Indoleamine 2,3-dioxygenase (IDO), a tryptophan catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders. IDO expression is induced by IFN-gamma and leads to neurotoxicity by generating quinolinic acid. Additionally, it inhibits the immune response through both tryptophan depletion and generating other tryptophan catabolites. IL-4 and IL-13 have been shown to control IDO expression by antagonizing the effects of IFN-gamma in different cell types. Here, we investigated the effects of these cytokines on IDO expression in microglia. Interestingly, we observed that both IL-4 and IL-13 greatly enhanced IFN-gamma-induced IDO expression. However, tryptophanyl-tRNA synthetase (WRS), which is coinduced with IDO by IFN-gamma, is downregulated by IL-4 and IL-13. The effect of IL-4 and IL-13 was independent of STAT-6. Modulation of IDO but not WRS was eliminated by inhibition of protein phosphatase 2A (PP2A) activity. The phosphatidylinositol 3-kinase (PI3K) pathway further differentiated the regulation of these two enzymes, as inhibiting the PI3K pathway eliminated IFN-gamma induction of IDO, whereas such inhibition greatly enhanced WRS expression. These findings show discordance between modulations of expression of two distinct enzymes utilizing tryptophan as a common substrate, and raise the possibility of their involvement in regulating immune responses in various neurological disorders.

Acute SIV infection of the brain leads to upregulation of IL6 and interferon-regulated genes: expression patterns throughout disease progression and impact on neuroAIDS.

The virus/host interactions during the acute phase of human immunodeficiency virus (HIV) infection help determine the course of disease. During this time period, virus enters the brain. Here, we report clusters of genes whose transcripts are significantly upregulated in the frontal lobe of the brain during acute simian immunodeficiency virus (SIV) infection of rhesus monkeys. Many of these genes are involved in interferon (IFN) and/or interleukin (IL)-6 pathways. Although neither IFNalpha nor IFNgamma are elevated in the brain, IL6 is increased. Both IFNalpha and IL6 are elevated in plasma during this acute phase. The upregulation of STAT1, verified by immunohistochemical staining, can be due to both central nervous system (CNS) (SIV and IL6) and peripheral (IFNalpha and IL6) causes, and can itself drive the expression of many of these genes. Examination of the levels of expression of the upregulated genes in the post-acute and long-term phases of infection, as well as in SIV encephalitis, reveals increased expression throughout SIV infection, which may serve to protect the brain, but can have untoward long-term consequences.

Regulation of indoleamine 2,3-dioxygenase expression in simian immunodeficiency virus-infected monkey brains.

The human immunodeficiency virus type 1-associated cognitive-motor disorder, including the AIDS dementia complex, is characterized by brain functional abnormalities that are associated with injury initiated by viral infection of the brain. Indoleamine 2,3-dioxygenase (IDO), the first and rate-limiting enzyme in tryptophan catabolism in extrahepatic tissues, can lead to neurotoxicity through the generation of quinolinic acid and immunosuppression and can alter brain chemistry via depletion of tryptophan. Using the simian immunodeficiency virus (SIV)-infected rhesus macaque model of AIDS, we demonstrate that cells of the macrophage lineage are the main source for expression of IDO in the SIV-infected monkey brain. Animals with SIV encephalitis have the highest levels of IDO mRNA, and the level of IDO correlates with gamma interferon (IFN-gamma) and viral load levels. In vitro studies on mouse microglia reveal that IFN-gamma is the primary inducer of IDO expression. These findings demonstrate the link between IDO expression, IFN-gamma levels, and brain pathology signs observed in neuro-AIDS.

Highly activated CD8(+) T cells in the brain correlate with early central nervous system dysfunction in simian immunodeficiency virus infection.

One of the consequences of HIV infection is damage to the CNS. To characterize the virologic, immunologic, and functional factors involved in HIV-induced CNS disease, we analyzed the viral loads and T cell infiltrates in the brains of SIV-infected rhesus monkeys whose CNS function (sensory evoked potential) was impaired. Following infection, CNS evoked potentials were abnormal, indicating early CNS disease. Upon autopsy at 11 wk post-SIV inoculation, the brains of infected animals contained over 5-fold more CD8(+) T cells than did uninfected controls. In both infected and uninfected groups, these CD8(+) T cells presented distinct levels of activation markers (CD11a and CD95) at different sites: brain > CSF > spleen = blood > lymph nodes. The CD8(+) cells obtained from the brains of infected monkeys expressed mRNA for cytolytic and proinflammatory molecules, such as granzymes A and B, perforin, and IFN-gamma. Therefore, the neurological dysfunctions correlated with increased numbers of CD8(+) T cells of an activated phenotype in the brain, suggesting that virus-host interactions contributed to the related CNS functional defects.

Regional and cellular expression of the mannose receptor in the post-natal developing mouse brain.

The mannose receptor, a glycoprotein expressed in a soluble and membrane form by macrophages, plays an important role in homeostasis and immunity. Using biochemical and immunohistochemical analyses, we demonstrate that this receptor, both in its soluble and membrane forms, is expressed in vivo in the post-natal murine brain and that its expression is developmentally regulated. Its expression is at its highest in the first week of life and dramatically decreases thereafter, being maintained at a low level throughout adulthood. The receptor is present in most brain regions at an early post-natal age, the site of the most intense expression being the meninges followed by the cerebral cortex, brain stem and the cerebellum. With age, expression of the mannose receptor is maintained in regions such as the cerebral cortex and the brain stem, whereas it disappears from others such as the hippocampus or the striatum. In healthy brain, no expression can be detected in oligodendrocytes, ependymal cells, endothelial cells or parenchymal microglia. The mannose receptor is expressed by perivascular macrophages/microglia and meningeal macrophages, where it might be important for the brain immune defence, and by two populations of endogenous brain cells, astrocytes and neurons. The developmentally dependent, regionally regulated expression of the mannose receptor in glial and neuronal cells strongly suggests that this receptor plays an important role in homeostasis during brain development and/or neuronal function.

Identification and functional characterization of the mannose receptor in astrocytes.

The immune competence of astrocytes is still ill defined, especially their endocytic capacity, a prerequisite for efficient antigen presentation. We show that mannose receptor, a very important conduit for internalization of infectious agents and self antigens, is functionally expressed in the murine CNS. By in vitro assays, astrocytes and microglia were shown to be the prime cells expressing this receptor. Studies on astrocytes demonstrate that its expression and function are inversely regulated by anti-and pro-inflammatory compounds. Downregulation of the mannose receptor by IFN-gamma is concomitant with the induction of the invariant chain, which is also induced by GM-CSF + IL-4. Mannose receptor-expressing astrocytes may thus act as scavenger not only in CNS development but also in defense, against soluble and particulate mannosylated pathogens, presenting fragments thereof at strategic locations in the CNS. These findings unravel a new and putatively very important role of astrocytes in innate immunity and possibly development.

Response of diminazene-resistant and diminazene-susceptible Trypanosoma congolense to treatment with diminazene when occurring as a mixed infection in goats.

A study was carried out to determine whether a drug-resistant trypanosome population could influence the survival of a drug-sensitive population in mixed infections in goats. To identify both populations during the course of a mixed infection, a system for distinguishing them was developed; using a nucleotide sequence of a cDNA that was derived from Trypanosoma congolense ILNat 3.3 (IL 1616), a pair of 20-mer primers was designed which, in a PCR, amplified a 900-bp sequence from the diminazene-sensitive trypanosome, T. congolense IL 1180, but not the diminazene-resistant trypanosome, T. congolense IL 3247. The PCR technique detected 100 pg of IL 1180 DNA when mixed with 25 ng of total genomic DNA of IL 3274, as determined by gel electrophoresis and ethidium bromide-staining of the PCR products. Using the 900-bp PCR product as a 32P-labelled probe on Southern blots, the sensitivity was increased 100-fold. Three groups of five goats each were infected with IL 1180 (group A), IL 3274 (group B) or both clones simultaneously (group C), and treated with diminazene aceturate at a dose of 7.0 mg/kg body weight following detection of trypanosomes. Three other groups of three goats each were similarly infected and kept as untreated controls. All group A animals were cured, while all in group B and four animals in group C relapsed. Trypanosomes were harvested from all animals at regular intervals up to 60 days post treatment. Using the PCR techniques, IL 1180 DNA could not be detected in any post-treatment trypanosome DNA sample. It therefore appeared, on the basis of the sensitivity of the DNA detection systems used, that IL 1180 is unable to survive treatment with diminazene aceturate when mixed with IL 3274 in goats.

Pharmacokinetics of melarsoprol in uninfected vervet monkeys.

The level of the trypanocidal drug melarsoprol was determined in serum and cerebrospinal fluid (CSF) of six healthy vervet monkeys after intravenous application of the drug following a standard treatment schedule and a recently suggested alternative protocol. The maximum serum levels measured were about 3 micrograms/ml. A three-compartment model was used to analyze the serum data. The mean residence time calculated for melarsoprol in serum was 18 h, the volume of distribution was 3.6 l/kg and the clearance was 3.5 ml/min*kg. In the CSF the drug levels were generally very low, not exceeding 55 ng/ml, and the adaptation of the drug levels was found to be very low. The comparison of the drug concentrations required to eliminate trypanosomes in vitro and the drug concentrations reached in the CSF during treatment revealed that the latter might be insufficient in some cases to eliminate all trypanosomes from this site. The peak serum levels during alternative application of the drug were lower compared to those during empirical treatment. No evidence for drug cumulation in the body was found. The results of this study are compared with recent pharmacokinetic data from human patients, and discussed in the context of the problem of relapses and reactive encephalopathy occurring after treatment of sleeping sickness.